A recent study has unveiled a promising liquid biopsy approach that assesses DNA-methylation levels in the blood to enhance early detection of pregnancies at risk of developing preeclampsia. Preeclampsia, a serious hypertensive disorder occurring during pregnancy, can pose risks to both the mother and fetus. It is typically diagnosed after the 20th week of pregnancy and is characterized by high blood pressure and proteinuria. This innovative technique offers a non-invasive alternative to surgical biopsies and has the potential to significantly improve the timely identification and management of preeclampsia, benefiting maternal and fetal health.
Facts/Terms for UPSC Prelims
- DNA-Methylation: DNA-methylation is a molecular modification of DNA molecules that can influence gene expression and plays a role in various biological processes, including disease development.
- Hypertension: Hypertension refers to high blood pressure, a common symptom of preeclampsia and a key factor in its diagnosis.
- Proteinuria: Proteinuria is the presence of an abnormally high level of protein in the urine, which is often observed in individuals with preeclampsia.
- Prevention of Preeclampsia: Low-dose aspirin is cited as the best clinical evidence for preventing preeclampsia. Additionally, lifestyle choices and maintaining overall health are important for those with a history of preeclampsia.
- Liquid Biopsy: A liquid biopsy is a non-invasive medical procedure that involves analyzing various biomarkers or genetic material in bodily fluids, such as blood, to detect or monitor diseases, including cancer and, as in this case, preeclampsia during pregnancy.